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ABSTRACT
Despite controversy on the correlation between p53 accumulation and TP53 
mutational status, immunohistochemical (IHC) detection of overexpressed protein 
has long been used as a surrogate method for mutation analysis. The aim of our 
study was to characterise the IHC expression features of TP53 somatic mutations 
and define their occurrence in human cancers. A large-scale database analysis was 
conducted in the IARC TP53 Database (R17); 7878 mutations with IHC features were 
retrieved representing 60 distinct tumour sites. The majority of the alterations were 
immunopositive (p <0.001). Sex was known for 4897 mutations showing a female 
dominance (57.2%) and females carrying negative mutations were significantly 
younger. TP53 mutations were divided into three IHC groups according to mutation 
frequency and IHC positivity. Each group had female dominance. Among the IHC 
groups, significant correlations were observed with age at diagnosis in breast, bladder, 
liver, haematopoietic system and head & neck cancers. An increased likelihood of 
false negative IHC associated with rare nonsense mutations was observed in certain 
tumour sites. Our study demonstrates that p53 immunopositivity largely correlates 
with TP53 mutational status but expression is absent in certain mutation types. 
Besides, describing the complex IHC expression of TP53 somatic mutations, our 
results reveal some caveats for the diagnostic practice.
INTRODUCTION
The TP53 gene (17p13) encodes a nuclear 
transcription factor expressed in response to various stress 
signals such as DNA damage, heat shock, hypoxia, and 
oncogene overexpression. Upon activation, p53 maintains 
the integrity and stability of the genome by triggering 
cell-cycle arrest, DNA repair, and apoptosis [1]. The 
393-amino-acid tumour-suppressor protein consists of 
an N-terminal transactivation domain (residues 1-42), 
a proline-rich domain (residues 40-92), a sequence 
specific core DNA binding domain (residues 103-306), 
a tetramerization domain (residues 307-355) and a 
C-terminal regulatory domain (residues 356-393) [2]. 
While other tumour suppressor genes are inactivated 
by mutations leading to absence of protein, TP53 
alterations are usually missense producing stable full-
length protein [3]. Somatic TP53 mutations primarily 
occur at the 175, 245, 248, 249, 273 and 282 ‘hotspot’ 
codons in the conserved DNA binding domain (DBD), 
but they can also happen in any other sites within the 
gene [4]. Extensive efforts have been made to study TP53 
mutation effect on prognosis, therapeutic response and its 
role in cancer diagnosis. It was previously reported, that 
p53 overexpression is a prognostic indicator in colorectal, 
lung, prostate, and breast carcinomas [5-7]. 
Fast and reliable detection is crucial for the accurate 
diagnostic decisions and targeted therapies [8]. There is 
an agreement that overexpressed p53 protein indicates 
the presence of TP53 alterations [9]. Wild-type p53 is 
an unstable protein with a short half-life for its detection 
by immunohistochemistry (IHC), but mutant p53 can 
accumulate within tumour cells creating a stable target 
for IHC [10]. Although nucleotide sequencing is the gold 
standard to identify TP53 mutations, due to its beneficial 
features IHC has long been used as a surrogate method for 
mutations analysis in histopathological diagnostic practice 
[11]. 
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Recent tumour profiling and data sequencing 
databases enable to more complex research, including 
molecular epidemiology, clinical surveys, and structural 
analyses [12, 13]. The International Agency for Research 
on Cancer (IARC) TP53 Mutation Database (http://p53.
iarc.fr/) contains data on the prevalence and patterns of 
more than 28000 somatic mutations in human cancers, 
annotations of tumour phenotype, patient characteristics, 
the structural and functional impact, and immunostaining 
of the mutations. The database includes all published 
TP53 mutations, all confirmed by sequencing, published 
in the peer-reviewed journals or compiled in mutation data 
repositories [1, 14].
The aims of our study were to characterise the IHC 
expression features of TP53 somatic mutations, and define 
their occurrences in human cancers. For this purpose, a 
large-scale analysis has been conducted involving the 
available p53 IHC and clinicopathological data in the 
IARC TP53 Database. Besides, describing the IHC 
expression characteristics of TP53 mutations, our results 
revealed some caveats of using p53 IHC as a surrogate for 
mutation analysis.
RESULTS
IHC expression characteristics of somatic 
mutations
Altogether, p53 IHC data was available in 7878 
mutations, representing 26.5% of the 29711 TP53 somatic 
mutations in the IARC Database. The IHC staining 
was positive in 6026 mutations (76.5%), whereas 1852 
mutations (23.5%) were negative by IHC (p < 0.001). 
A key purpose of this study was to provide a complex 
characterisation of IHC patterns of TP53 mutations. 
Regarding mutation types, single nucleotide alterations 
were predominantly IHC positive at a range between 
74.9% and 84.6%; tandem (93.8%) and complex mutations 
were also positive, whereas deletions and insertions 
were mostly negative (57% and 59.7%, respectively). 
As expected, 88% of missense mutations were p53 IHC 
positive, whereas 71.2% of nonsense mutations were 
negative for IHC (p < 0.001). 
Figure 1: Classification of TP53 somatic mutations based on frequency and IHC positivity in IARC TP53 Database. 
Somatic TP53 alterations were categorized into three groups: ‘hot spot’ mutations (marked with blue triangle) are frequent in Group A 
(mutation frequency ≥ 0.013 and IHC positivity ≥ 0.85); common nonsense mutations (blue circles) are in Group B (mutation frequency 
≤ 0.011 and IHC positivity ≤ 0.44); less frequent and mostly positive missense mutations (yellow square) fall into Group C (mutation 
frequency ≤ 0.072 and IHC positivity ≥ 0.74). Each data point represents distinct TP53 mutations and only individual mutations with 15 or 
more IHC results were considered.
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Table 1: Immunohistochemical expression characteristics of TP53 mutations.
Mutation 
features 
p53 immunohistochemistry
p-valueaTotal (n = 7878) Negative (%) (n = 1852) Positive (%) (n = 6026)
Exons/introns
exons 7690 1745 (22.69) 5945 (77.31)
0.001introns 186 105 (56.45) 2086 (43.55)
NA 2 2 (100.00) 0 (0.00)
CpG site
no 5373 1433 (26.67) 3940 (73.33) < 0.0001
yes 2505 419 (16.73) 2086 (83.27) < 0.0001
Splice site     
alternative 71 12 (16.90) 59 (83.10) 0.1872
consensus 112 72 (64.29) 40 (35.71) < 0.0001
criptic 62 16 (25.81) 46 (74.19) 0.6684
no 7633 1752 (22.95) 5881 (77.05) < 0.0001
Type
Single nucleotide mutationsb 6860 1324 (19.30) 5536 (80.70) <0.0001
tandem 97 6 (6.19) 91 (93.81) 5.16E-05
complex 48 18 (37.50) 30 (72.50) 0.0219
deletion 667 380 (56.97) 287 (43.03) <0.0001
insertion 196 117 (59.69) 79 (40.31) <0.0001
NA 10 7 (70.00) 3 (30.00) 0.000522
Effects
frameshift 677 451 (66.62) 226 (33.38) <0.0001
intronic 53 25 (47.17) 28 (52.83) 4.58E-05
large deletion 2 2 (100.00) 0 (0.00) 0.0107
missense 5889 707 (12.01) 5182 (87.99) <0.0001
nonsense 552 393 (71.20) 159 (28.80) <0.0001
silent 367 136 (37.06) 231 (62.94) 3.64E-10
splice 131 86 (65.65) 45 (34.35) <0.0001
other 177 44 (24.86) 133 (75.14) 0.6683
NA 30 8 (26.67) 22 (73.33) 0.6828
Structural motif     
C-terminal 234 104 (44.44) 130 (55.56) <0.0001
C- terminal/NLS 31 13 (41.94) 18 (58.06) 0.0153
C- terminal/tetramerization 101 39 (38.61) 62 (61.39) 3.15E-04
L1/S/H2 1693 234 (13.82) 1459 (86.18) <0.0001
L2/L3 2765 434 (15.70) 2331 (84.30) <0.0001
N- terminal 34 26 (76.47) 8 (23.53) <0.0001
N- terminal/Transactivation 33 20 (60.61) 13 (39.39) <0.0001
N- terminal/Transactivation/ NES 5 2 (40.00) 3 (60.00) 0.3844
NDBL/β-sheets 2657 795 (29.92) 1862 (70.08) <0.0001
SH3-like/Proline-rich 101 60 (59.41) 41 (40.59) <0.0001
NA 224 125 (55.80) 99 (44.20) <0.0001
aComparisons between groups were performed with Pearson’s Chi-square (χ2), Significant p-values are marked in bold; bContaining the 
following point mutations: A:T>C:G, A:T>G:C, A:T>T:A, G:C>A:T, G:C>A:T at CpG, G:C>C:G and G:C>T:A)
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Almost eighty percent (77.3%) of the mutations 
were positive within the coding regions (e.g. exons 2-11), 
whereas the majority of alterations in the non-coding 
sequences were negative (56.5%) for IHC (p = 0.001) 
(Supplemental Figure S1). Mutations outside and within 
the CpG island regions were positive in 83.3% and 73.3%, 
respectively (p < 0.001). TP53 mutations were positive 
in non-splice site sequences as well as in alternative and 
cryptic sites (77%, 83.1% and 74.2%, respectively), but 
64.3% of the mutations were negative in the consensus 
splice sites. The IHC expression patterns were diverse 
among the structural motifs of mutated p53. 
Mutations were unequivocally positive in L1/S/H2 
(86.2%), L2/L3 loops (84.3%), and NDBL/beta-sheets 
motifs (70.1%). Furthermore, alterations were positive 
in the C-terminal (55.6%), C-terminal/NLS (58.1%), and 
N-terminal/Transactivation/NES (60%) motifs. On the 
other hand, TP53 mutations were mostly negative in the 
N-terminal (76.5%), N-terminal/Transactivation (60.6%), 
and SH3-like/Proline-rich (59.4%) motifs. The structural 
motifs of 224 mutations were non-available (Table 1). 
IHC expression patterns of individual somatic 
TP53 mutations
Our other purpose was to describe the IHC 
expression profile of individual TP53 mutations and 
compare their clinico-pathological features in various 
tumour sites. First, we estimated the frequencies of each 
1778 individual TP53 mutations in the IARC database. 
Second, the IHC results were retrieved from the database. 
IHC expression patterns were available of 1139 individual 
TP53 mutations. Finally, we associated the alterations with 
their expression patterns. IHC data and frequencies of 
TP53 somatic mutations are summarized in Supplemental 
Table S1. 
The majority of the mutations in hotspot p53 codons 
were strongly positive: 175 (89.7%), 245 (90.7%), 248 
(93.3%), 249 (88.0%), 273 (92.6%) and 282 (90.9%). 
In contrast, mutations were usually negative among the 
frequently altered codons like 213 (57.7%), 196 (65.2%), 
306 (60.9%), 146 (63.6%) and 298 (60.7%). More 
specifically, all alterations within the hotspot codons 
(R175H, G245S/D, R248Q/W/L, R249S, R273H/C/L, 
and R282W) were positive for p53 IHC at a range of 87.2-
100%. Contrary, frequent nonsense mutations such as 
R213*, R196*, R306*, W146*, and E298* were not able 
to be detected (63.4-75.6%) by immunohistochemistry. 
Based on the mutation frequencies and IHC 
positivity, TP53 mutations possess more than 15 IHC data 
(n = 78) were categorized into three distinct groups. Hot-
spot and IHC positive mutations (9/78; 11.5%) were in 
Group A, frequent and mostly IHC negative mutations 
(7/78; 9%) were in Group B, whereas infrequent and 
IHC positive mutations were in Group C (62/78; 79.5%) 
Figure 2: Significant differences of mean age of TP53 mutation carriers between IHC groups were found in five tumour 
sites. Bar graphs represent data in mean ± standard deviation (SD). Level of significance: * (p < 0.05), ** (p < 0.01), and *** (p < 0.001).
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(Figure 3). Principal components analysis of the groups 
by two components also confirmed differences between 
the three groups (Supplemental Figure S3). All alterations 
in Group A and C were missense, whereas in Group B 
they were nonsense (p < 0.001). The majority of TP53 
mutations in Group A and B localized within exons 5-8 
(p < 0.001), and they commonly occurred in the CpG 
sequences (p < 0.001).
Clinicopathological features of p53 IHC groups
Sex was available for 4897 TP53 mutations with 
known IHC data, including 2797 females (57.2%) and 
2097 males (42.9%). The p53 IHC was predominantly 
positive (75.8% vs. 76.4%) in both sex but females with 
IHC negative mutations were significantly younger (55.90 
± 15.391 vs. 58.57 ± 15.062 years, p = 0.0182). There was 
no significant difference regarding the mean age (56.44 
± 16.86 vs. 57.22 ± 15.772, p = 0.204). TP53 alterations 
were IHC positive in almost all human cancers in the 
database at a range between 50 and 100%. 
Sex distribution and the mean age at diagnosis 
were also evaluated in the three p53 IHC groups. A 
significant female dominance was observed in all groups 
(p = 0.0042). Significant differences were observed in five 
tumour sites (breast, bladder, haematopoietic system, liver, 
head and neck) in term of the age at diagnosis among the 
IHC groups (Figure 2). Breast cancer patients carrying 
nonsense mutations (Group B) were significantly younger 
(48.83±13.69 years) than patient in the other groups 
Figure 3: Frequency differences of nonsense TP53 (Group B) mutations across tumour sites. The ’heat map’ shows the 
different frequency of the seven nonsense TP53 mutations (ranging from -3 to 3) across tumour sites (compared to their overall frequency 
in IARC database). A heat-map of nonsense TP53 mutations were constructed using Gene-E version 3.0.204 (http://www.broadinstitute.
org/cancer/software/GENE-E/index.html). Level of significance: * (p < 0.05), ** (p < 0.01), and *** (p < 0.001).
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(Group A: 55.06±13.99 years & Group C: 55.97±14.07 
years). Similar difference was observed in bladder cancer, 
but patients were notable younger in only Group B 
(59.52±14.20 years) compared to Group A (64.44±12.57 
years). Contrary, liver carcinoma patients in Group A 
were significantly older then in Group C. Comparison of 
the Group A and C revealed that patients with frequent 
missense mutations were younger with haematopoietic 
system, but older with head and neck tumours. Mean 
ages in different IHC mutation groups are summarized in 
Supplemental Table S3.
Because the majority of nonsense TP53 mutations 
were undetectable by IHC and carriers usually have 
worse overall survival and a poor prognosis, further 
characterisation of nonsense mutations in Group B was 
also important. Significant differences were observed 
between the total frequencies of the mutations in the 
IARC Database and their frequency in several tumour 
sites (Figure 3). For example, R213* was more common 
in breast, colorectum, colon, and less frequent in liver, 
lung compared to its overall frequency. Frequencies 
of nonsense mutations at various tumour sites are 
summarized in Supplemental Table S4. 
DISCUSSION
Despite the numerous studies, the association 
between TP53 mutations and p53 nuclear accumulation is 
still not fully understood. Although immunohistochemistry 
is commonly used as a surrogate for TP53 mutation 
analysis in the routine diagnostic work-up, its reliability 
is controversial due to the false-positive and negative 
cases. The aim of our study was to estimate the 
immunohistochemical expression patterns of TP53 
somatic mutations at various tumour sites and correlate 
them with clinicopathological features. Therefore, we 
performed a comprehensive evaluation of the R17 dataset 
from the IARC TP53 Database [1, 14]. 
In normal conditions, synthesis and degradation 
of p53 are strictly regulated, its expression level is 
maintained very low [15]. Aberrant p53 has a prolonged 
turnover resulting in an overexpressed protein that can 
be detected by IHC [16]. Our study confirm that more 
than 75% of TP53 mutations showed IHC-detectable p53 
accumulation in a unified manner. This absolute positivity 
was also observed in all tumour sites. This is in contrast 
with other tumour suppressor genes where mutations are 
mostly deletions or nonsense leading to a decreased or 
absent protein expression [3].
The majority of TP53 mutations are predominantly 
clustered in the DNA binding domain (residues 94-292) 
[1]. In our results, over 94% of the IHC positive alterations 
also occurred in this domain (Supplemental Figure S2). 
The DNA-binding domain includes three particularly 
important regions. The L2 loop (codons 163-195) is 
required for the folding and stabilization of the central 
part of the protein, whereas L3 loop (codons 236-251) 
and loop-sheet-helix (L1/S/H2) motif (codons 273-286) 
can contact the DNA at least two residues (241, 248 and 
273, 280, respectively). TP53 mutations in these domains 
are associated with a more aggressive clinical phenotype, 
presumably they decrease biological activity of the protein 
[17, 18]. As indicated in Table 1, mutations within these 
crucial motifs are mostly positive by IHC.
The majority of TP53 mutations occur within exons 
5-8 [4]. In our study, more than 95% of the alterations 
localized within these exons and showed IHC positivity. 
Point mutations in TP53 introns can abrogate the function 
of any remaining normal p53 [19]. Our findings are 
consistent with previous reports, because 87% of the IHC-
detectable mutations were single base-pair substitutions in 
coding regions. These are missense mutations that usually 
produce full-length proteins, consequently, more than 
80% of the alterations were also IHC positive according 
to the IARC database. Besides, the majority of tandem and 
complex TP53 mutations are also IHC positive, however, 
they are relatively infrequent in human cancer [1]. Splice 
mutations in the TP53 are reported as infrequent events. 
Accordingly, only the 3% of the mutations occurred 
within the conserved dinucleotides involved in splice 
sites and their distribution and IHC characteristics were 
diverse. The altered transcript is sufficiently stable and 
not degraded [20]. Splicing alterations in the alternative 
and cryptic splice acceptor sites showed IHC positivity; 
in contrast, they were negative in consensus splice sites. 
There was no remarkable difference in IHC expressions 
with respect to the position of the mutation within or 
outside CpG sequences, both of them were mostly positive 
(in 83.3% and 73.3%, respectively). 
We also analysed the association between individual 
TP53 mutations and their IHC characteristics. For this 
reason, somatic TP53 mutations in the IARC database 
were classified into three groups based on their frequency 
and IHC positivity. The “hotspot” mutations (Group A) 
and frequent nonsense mutations (Group B) formed 
distinct groups, whereas the infrequent strongly positive 
missense mutations were in Group C (Figure 1). The 
key starting point of our study was that nonsense TP53 
mutations (Group B) result in lack of immunolabelling due 
to the absence of gene product [21]. Truncating mutations 
of genes like NF2 or HNF1A are associated with an early 
age of onset [22, 23]. However, TP53 mutations were 
predominantly IHC positive in both sexes. Females with 
IHC negative mutations (manly caused by truncating 
mutations) were younger. According to our classification 
of TP53 mutations, the age at diagnosis of Group B was 
lower in breast and bladder cancers, and interestingly, 
it was higher in tumours of the haematopoietic system 
compared to Group A and C. The frequency of R213* and 
Q192* was also increased in breast, as well as R306* and 
Q192* mutations frequency in bladder cancer. In breast 
cancer, R213* TP53 mutations are more frequent in the 
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basal-like subtype [17]. In colon cancer, R196*, R213* 
and R306* mutations were also common. Furthermore, 
R213* mutation was common in colorectum, and R306* 
in rectum carcinomas. Vakiani et al. reported, that 
R306*mutation was present in 15.27% and 39.5% of 
alleles in the invasive component of the primary tumour 
and in the metastasis, respectively [18]. The W146* 
mutation was slightly more frequent in skin and mouth 
cancers in our analysis. 
Although nonsense (Group B) mutations are 
infrequent, they indicate worse overall survival especially 
if p53 is truncated [24, 25]. Nadkarni et al. showed, that 
TP53 null mutations presumably related to recurrent 
tumours. Their works indicate that deleterious alteration 
confers an increased and earlier probability for recurrence 
[26]. Furthermore, tumours with nonsense (Group B) 
mutations are more likely to develop metastatic tumours 
compared to those cancers that contain either missense 
mutations (Group A & C) or are wild-type p53 [27]. 
Moreover, patients harbouring null TP53 alterations 
have an increased risk to have more vascular tumours 
[26]. The effect and importance of TP53 mutations are 
summarized in a review paper by Muller and Vousden 
[28]. As anticipated, more than half of the alterations 
(56.5%) in the non-coding regions were mostly negative 
by IHC. We demonstrated that TP53 mutations with 
negative IHC results were most frequently caused by 
deletions or insertions (Table 1). Drugs inducing the 
read-through of early stop codons caused by mutations 
could be a promising therapeutic strategy of the cancer 
linked with non-sense mutations in tumour suppressor 
genes. Aminoglycoside antibiotics such as gentamicin 
and G418 can promote premature termination codon read-
through results in the partial restoration of full-length 
protein [29]. Floquet et al. described that Q192*, R213* 
and E298* TP53 mutations displaying high induced 
read-through level [30]. The aminoglycoside treatment 
strongly and specifically stabilized mutant p53 mRNAs 
that would otherwise be degraded by non-sense mediated 
mRNA decay [30]. Although induction of read-through of 
premature stop codons is effective, the clinical use of these 
agents is still limited by their toxicity [31]. 
Currently, there is no consensus as to which 
antibodies are most appropriate for evaluating mutation-
associated p53 expression [24]. None of the routinely 
used p53 antibodies (CM1, Pab1801, DO1 and DO7) 
differentiate between mutant and wild-type p53 proteins 
[2, 21]. While, CM1 antibody binds to the full length 
protein, DO7, DO1 and Pab1801 recognize epitopes 
only in the N-terminus of the human p53 protein (amino 
acid residues 1-45, 11-25 and 32-79, respectively) [32-
34] (Supplemental Figure S2). Importantly, the most 
commonly used DO7 antibody can detect only truncation 
mutations in exons 9-10 [24]. A further limitation of p53 
IHC is that not only TP53 mutation but also disturbed 
p53 pathway can result in abnormal p53 expression [35]. 
Therefore, amplification of MDM2 or MDM4 as well 
as repressed p14ARF or TP53 by promoter methylation 
can cause reduced p53 expression resulting in a limited 
sensitivity of IHC [36, 37]. 
Intensive efforts have been made to improve the 
reliability of p53 IHC as a surrogate method. Combined 
usage of antibodies that target various p53 epitopes or 
p53-related proteins, as well as quantitative scoring 
methods seem to be valuable approaches for TP53 
mutation prediction. In 2005, Nenutil et al. applied a 
panel of eight antibodies that relate to p53 stabilization 
and transcriptional activation: anti-p53 (DO1; Bp53-10 & 
Pab1801; Ser15; Ser392), anti-Ki67 (MIB1), anti-MDM2 
(2A9) and anti-p21 (118) [38]. They conclude that i) 
overexpressed p53 without increased MDM2 indicates 
inactivating mutations that stabilize p53; ii) tumours with 
overexpressed p53 and concurrent increase of MDM2 do 
not have p53 mutation. iii) phosphorylated p53 expression 
correlates with total p53 levels and iv) does not predict 
TP53 mutation status [38]. Nevertheless there are no 
subsequent studies confirming these findings. Wertz et 
al. described, that a cocktail of DO1 and DO7 antibodies 
could identify 93% of cell lines and patient samples with 
TP53 missense mutations in the exons 5 to 8 region in 
prostatic adenocarcinoma [39]. Combined IHC of PLK1 
(Polo-like kinase-1), p21, and p53 is slightly more 
sensitive for predicting TP53 status and may facilitate 
differentiation of missense and nonsense mutations [40]. 
The p21 is a transcriptional target of p53, therefore its 
expression is used for decreasing false positivity of p53 
IHC. Immunohistochemical positivity of PLK1 along with 
negative p53 IHC can reflect nonsense TP53 mutations 
and may decrease the possibility of false negative IHC, 
because mutant p53 fails to repress PLK1 expression [41]. 
Köbel et al. used p53 antibodies DO7, DO1, and E26 and 
tagged-amplicon next generation sequencing of TP53 in 
high-grade serous ovarian carcinomas and endometrioid 
carcinomas. They demonstrated that optimized p53 IHC 
assay is a useful surrogate for the TP53 mutation status, 
and that combination of p53 IHC and sequencing should 
be the gold standard in assessing the p53 functional 
status for clinical trial inclusion [42]. IHC scoring may 
correlate with TP53 mutations and could increase the 
accuracy of p53 IHC. In a recent study, Cole et al. (2016) 
combined massively parallel sequencing and IHC to 
characterise TP53 mutations and p53 expression in high-
grade serous ovarian cancer. According to their results, 
missense TP53 mutations have high expression of p53, 
whereas low expression was associated with non-missense 
mutations (i.e. frameshift, in-frame, nonsense, and 
splice). Furthermore, wild-type TP53 tumours displayed 
intermediate p53 IHC expression [43].
A limitation of our analysis is that we cannot 
predict the overall, and tumour specific sensitivity of p53 
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immunohistochemistry because the IARC TP53 Database 
does not contain IHC results of wild-type p53 expression. 
Consequently, the analysis and exclusion of false positive 
cases has not been possible. IHC antibodies are not listed 
in the database, therefore their specificity and association 
with somatic mutations could not be analysed. 
In summary, the majority of TP53 mutations were 
missense and IHC positive, whereas most nonsense and 
frameshift mutations and deletions were immunonegative. 
Significant correlations were observed between the age 
at diagnosis and the immunohistochemical patterns of 
TP53 mutations in breast, head & neck, bladder, liver and 
haematopoietic cancers. In certain tumour sites there is 
an increased likelihood of false negative IHC associated 
with rare nonsense mutations. Our frequency- and 
immunopositivity-based classification is useful in patient 
stratification and has prognostic implication.
MATERIALS AND METHODS
The IARC TP53 somatic mutation database
The last realised (R17) dataset of somatic TP53 
mutation (http://p53.iarc.fr/TP53SomaticMutations.
aspx) was used for the characterisation of TP53 somatic 
mutations, and correlate them with IHC expression 
data. Of the 29711 mutations, the protein description is 
available in 25361 mutations which are composed of 1778 
unique TP53 mutations. The nomenclature is at the protein 
level according to the Human Genome Variation Society 
(HGVS) standards, using the P04637 Uniprot reference 
sequence.
Immunohistochemical characteristics of somatic 
TP53 mutation
Somatic TP53 mutations with known IHC data 
were retrieved and the expression patterns were analysed 
in various aspects, such as the localization within the 
TP53 gene (exons/introns, CpG and splice sites); effects 
(frameshift, intronic, large deletion, missense, nonsense, 
silent, splice, other); type (single nucleotide mutations, 
tandem, complex, deletion, insertion); and affected 
structural motifs of p53 protein (C-terminal, C-terminal/
NLS, C-terminal/tetramerization, L1/S/H2, L2/L3 loops, 
N-terminal, N-terminal/Transactivation, N-terminal/ 
Transactivation/ NES, NDBL/β-sheets, SH3-like/Proline-
rich). 
In the IARC database, p53 immunostaining is 
graded as ‘positive’ (n = 6026), ‘negative’ (n = 1852) and 
‘+/-’ (n = 205). To improve the accuracy of our study only 
‘positive’ and ‘negative’ p53 IHC results were considered. 
Based on these criteria, of the 29711 mutations IHC 
data are available for 7878 TP53 somatic mutations 
corresponding to 1139 distinct alterations. TP53 somatic 
mutations frequencies and their IHC data are summarized 
in Supplemental Table S1. The majority of the alterations 
(91.9%) are clustered within exons 5-8. More than two-
thirds of the mutations (68.2%) occur in non-CpG sites, 
and 96.9% of the alterations are non-splice site mutations. 
Considering the mutation types, 6860 (87.1%) are single 
nucleotide substitutions (SNSs), 667 (8.5%) deletion, 
196 (2.5%) insertion, 97 (1.2%) tandem and 48 (0.6%) 
complex mutation. Mutation type was non-available only 
in 10 mutations (0.1%). The most common mutation 
effect is missense (74.8%), followed by frameshift (8.6%), 
nonsense (7%), silent (4.7%), splicing (1.7%), intronic 
mutations (0.7%) and large deletion (0.03%). Further 
2.3% of the mutations is specified as ‘other’ and 0.4% of 
the alterations remains undetermined (Table 1). 
Clinicopathological characteristics of TP53 
mutations with known IHC data
 The subset of mutations with p53 IHC results 
compiles data on 7124 individuals. Sex is available for 
4894 individuals (62.1%) including 2797 females (57.2%) 
and 2097 males (42.9%). The mean age at diagnosis is 
56.90 ± 16.23 years given for 3072 patients (62.8%) (Table 
2). The available p53 IHC expression data are distributed 
among 60 tumour sites (Supplemental Table S2). 
Information about the sample source is available for 6957 
Table 2: Comparison of p53 immunohistochemistry data with sex distribution and mean age of patients with TP53 
somatic mutations based on the IARC TP53 Database (R17).
p53 IHC Male Female p-value
Mean age at 
diagnosis (SD)
negative 58.567(± 15.062)
55.896
(± 15.391) 0.0182a
positive 57.220(± 15.772)
56.439 
(±16.860) 0.2646a
p53 IHC (%)
negative 496(23.65%)
691
(24.71%) 0.8851b
positive 1601(76.35%)
2106
(75.29%)
(IHC=immunohistochemistry; SD=Standard deviation; aMann-Witney U-test; bPearson’s chi square test; Significant p-values 
are marked in bold)
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cases: surgery (83.3%), biopsy (13.5%), cell-line (2.7%), 
blood (0.3%), bone marrow (0.1%), xenograft (0.1%), 
pleural fluids (0.03%) and saliva (0.01%). Overall, 5211 
mutations have a known origin: 4977 (95.5%) primary 
tumours, 106 (2%) metastasis, 84 (1.6%) recurrent, and 
44 (0.8%) secondary tumours. 
Classification of TP53 mutations based on 
frequency and IHC patterns
We investigated the frequency of 1139 distinct 
TP53 mutations in the IARC Database and IHC positivity 
of individual mutations was also calculated by dividing 
the IHC positive cases by the total number of the given 
mutation (Supplemental Table S1). Based on these 
characteristics, we divided TP53 somatic mutations into 
three groups: 1.) Group A (strongly IHC positive, hot-
spot mutations; mutation frequency ≥ 0.013 and IHC 
positivity ≥ 0.85), 2.) Group B (mainly IHC negative 
nonsense mutations; mutation frequency ≤ 0.011 and IHC 
positivity ≤ 0.44) and 3.) Group C (IHC positive, non-
frequent missense mutations; mutation frequency ≤ 0.072 
and IHC positivity ≥ 0.74). Only individual mutations with 
15 or more IHC results were involved in the classification. 
To evaluate these two components we applied principal 
component analysis (PCA).
Statistical analysis
Dataset of TP53 somatic mutations was downloaded 
and extracted using Microsoft Excel version 2013 
(Microsoft Corp, Redmond, Washington, USA) and the 
statistical analysis was performed using SPSS 19.0 (SPSS 
Inc., Chicago IL) for Windows and R statistical software 
(www.R-project.org). Comparisons between groups 
were performed with Pearson’s Chi-square (χ2) test for 
categorical variables. Age of onset associations between 
groups were done with the Mann-Whitney U test. Two-
sided tests were computed and statistical significance 
was set at p < 0.05. The difference in proportions was 
compared using 2-sample test for equality of proportions 
with continuity correction. 
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